CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 50 enrolled
Drug / intervention
Liposomal bupivacaine (LB)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03692546
NCT03692546N/ACompleted

Liposomal Bupivacaine Reduces Opiate Consumption After Rotator Cuff Repair in a Randomized Control Trial

Orthopaedic & Neurosurgery Specialists·interventional·Posted Oct 2, 2018·Updated Oct 2, 2018

In Brief

A clinical study evaluating Liposomal bupivacaine (LB) for Rotator Cuff Tear and Postoperative Pain. Completed, enrolled 50 participants across 1 site.

Detailed Summary

The use of an interscalene block (ISB) is often associated with rebound pain that could be avoided through adjunctive therapy with longer duration. Administration of a liposomal bupivacaine (LB) field block in addition to ISB would overcome this rebound pain to provide greater pain relief and reduce opiate consumption when compared to ISB alone. 50 patients were recruited and randomized into groups that either received or did not receive an intraoperative LB field block in addition to standard ISB administration. Visual Analog Scale (VAS) pain scores and narcotic consumption were recorded over the five-day postoperative period to determine the effectiveness of LB pain relief.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedOct 2, 2018
Enrollment StartFeb 1, 2017
Primary CompletionMar 1, 2018
Study CompletionSep 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 7.8 years ago

Interventions

Liposomal bupivacaine (LB)drug

Addition of LB solution to soft tissue surgical field block to a standard interscalene block procedure